Biohaven Ltd. (BHVN) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Biohaven Pharmaceuticals fourth quarter and full year 2021 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. If anyone should require operator assistance, please press star zero on your telephone keypad. Please be advised that today's conference will be recorded. I would now like to hand the conference over to Caroline Dirks from Biohaven. Thank you, Caroline. Please go ahead. Thank you, and welcome to the BioHaven fourth quarter and full year 2021 earnings call. Speaking on today's call are Dr. Vlad Chorich, our Chief Executive Officer, Matthew Butin, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Dr. Elise Stock, Chief Medical Officer. Also speaking on today's call are Dr. Michael Bozic and Dr. Stephen Dworski, who will be joining BioHaven as President, Biohaven Labs, and Senior Vice President, Biohaven Labs, respectively, and Cliff Bechtold, President and General Manager, Biohaven Ireland. We are also pleased to announce the addition of Jennifer Porcelli to Biohaven Pharmaceuticals as Vice President, Investor Relations. Earlier this morning, we issued a press release announcing the fourth quarter 2021 highlights and a summary of year-end results. A copy of this press release can be found on our website at biohavenpharma.com, and we will file our Form 10-K later today. Before we begin, let me remind everyone that today's discussion contains forward-looking statements based on the environment as we currently see it, and includes risks and uncertainties. A list and description of risks and uncertainties associated with an investment in Biohaven can be found in the company's filings with the U.S. Securities and Exchange ...